학술논문
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Document Type
Artikel
Author
Source
Gut. 65(11):1861-1870
Subject
Language
English
English
English
ISSN
1468-3288